A clinical trial published earlier this month in Nature Medicine, suggesting that the timing of cancer immunotherapy infusions could significantly impact their effectiveness, is now under investigation following concerns raised about the study’s data and design. The trial reported that lung cancer patients receiving treatment in the morning experienced a substantial reduction in risk of disease progression compared to those treated in the afternoon.
Multiple scientists have since identified inconsistencies in the trial’s documentation, prompting Nature Medicine to append a note on Thursday stating It’s investigating the allegations. Concerns center on discrepancies between the trial’s registration on clinicaltrials.gov and the submitted protocol, chronological errors within the protocol itself, and anomalies in the reported progression-free survival and adverse event data.
Angus Chen, reporting for STAT, noted that the study’s initial findings – that a simple adjustment to infusion timing could boost immunotherapy response – were met with both interest and skepticism. The biological plausibility of such a connection was already questioned by experts prior to the emergence of data concerns.
The study authors declined to comment directly on the criticisms, informing STAT in an email that they are preparing a response to Nature Medicine. The investigation comes as the field of cancer immunotherapy continues to evolve, with researchers seeking ways to maximize the effectiveness of these increasingly important treatments. At the 2025 American Society of Clinical Oncology (ASCO) meeting, attendees expressed both optimism and concern regarding the future of cancer therapies, according to reporting from STAT News.
The scrutiny of this particular trial also arrives at a time when funding for cancer research, including immunotherapy, faces potential cuts, as highlighted by a recent STAT report. These funding challenges could hinder the development of new and innovative cancer treatments, adding further urgency to ensuring the integrity of existing research.
Recent research, including a 20-year investigation led by Miriam Merad, is also working to rewrite the rules of cancer immunotherapy, according to STAT News. This ongoing work underscores the complexity of the immune system and the challenges involved in harnessing its power to fight cancer.
